WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Revenue

WuXi Biologics had revenue of 11.79B CNY in the half year ending June 30, 2026, with 37.47% growth. This brings the company's total for the last twelve months to 23.62B, up 17.80% year-over-year. In the year 2025, WuXi Biologics had annual revenue of 21.79B with 16.68% growth. That makes WuXi Biologics the 3,425th largest company in the world by revenue and 228th in Hong Kong.

• Revenue (ttm): 23.62B CNY
• Revenue Growth: +17.80%
• P/S Ratio: 7.43
• Revenue / Employee: 1.61M CNY
• Employees: 14,705
• Market Cap: 187.05B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Segment

By Segment

Chart

• Biologics 18.14B 75.3%
• Xdc 5.94B 24.7%

By Geography

Chart

• North America 12.65B 58.1%
• Europe 5.04B 23.1%
• People's Republic of China (PRC) 2.68B 12.3%
• Rest of The World 1.41B 6.5%

Fiscal year ended Dec 31, 2025 See the full WuXi Biologics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	21.79B	3.11B	16.68%
Dec 31, 2024	18.68B	1.64B	9.63%
Dec 31, 2023	17.03B	1.77B	11.56%
Dec 31, 2022	15.27B	4.98B	48.38%
Dec 31, 2021	10.29B	4.68B	83.35%

Data Source: S&P Global Market Intelligence Last updated: Sep 22, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 20, 2026

Data Sources Report a data error